

Thomas S Stroup

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3890970/thomas-s-stroup-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

32,081
citations

67
h-index

179
g-index

196
ext. papers

38,217
ext. citations

8.9
avg, IF

7.9
L-index

#	Paper	IF	Citations
185	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014 , 511, 421-7	50.4	5249
184	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , 2005 , 353, 1209-23	59.2	4423
183	LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. <i>Nature Genetics</i> , 2015 , 47, 291-5	36.3	2096
182	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013 , 45, 984-94	36.3	1628
181	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011 , 43, 969-76	36.3	1508
180	Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005 , 80, 19-32	3.6	885
179	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , 2006 , 355, 1525-38	59.2	875
178	Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007 , 64, 633-47		781
177	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-610	11.9	682
176	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015 , 97, 576-92	11	649
175	Physical health monitoring of patients with schizophrenia. <i>American Journal of Psychiatry</i> , 2004 , 161, 1334-49	11.9	646
174	Microduplications of 16p11.2 are associated with schizophrenia. <i>Nature Genetics</i> , 2009 , 41, 1223-7	36.3	550
173	Premature Mortality Among Adults With Schizophrenia in the United States. <i>JAMA Psychiatry</i> , 2015 , 72, 1172-81	14.5	535
172	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017 , 49, 27-35	36.3	530
171	A national study of violent behavior in persons with schizophrenia. <i>Archives of General Psychiatry</i> , 2006 , 63, 490-9		505
170	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. <i>Schizophrenia Bulletin</i> , 2003 , 29, 15-31	1.3	462
169	Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. <i>American Journal of Human Genetics</i> , 2014 , 95, 535-52	11	411

168	A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. <i>Schizophrenia Research</i> , 2005 , 80, 45-53	3.6	406
167	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006 , 86, 15-22	3.6	389
166	Baseline neurocognitive deficits in the CATIE schizophrenia trial. <i>Neuropsychopharmacology</i> , 2006 , 31, 2033-46	8.7	374
165	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-10	11.9	359
164	Barriers to employment for people with schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 411-7	11.9	327
163	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008 , 13, 570-84	15.1	308
162	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-622	11.9	283
161	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. <i>Schizophrenia Research</i> , 2008 , 101, 273-86	3.6	222
160	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 2080-9	11.9	218
159	Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 428-36	11.9	212
158	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008 , 193, 279-88	5.4	200
157	Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. <i>Schizophrenia Bulletin</i> , 2009 , 35, 336-46	1.3	198
156	The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1751-62	4.6	184
155	Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. <i>American Journal of Psychiatry</i> , 2011 , 168, 831-9	11.9	180
154	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008 , 105, 175-87	3.6	179
153	The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. <i>Schizophrenia Research</i> , 2005 , 80, 9-18	3.6	157
152	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-22	11.9	153
151	Relationship of cognition and psychopathology to functional impairment in schizophrenia. <i>American Journal of Psychiatry</i> , 2008 , 165, 978-87	11.9	149

150	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008 , 193, 37-43	5.4	146
149	Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i> , 2018 , 17, 341-356	5.4	146
148	Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. <i>Schizophrenia Research</i> , 2009 , 107, 22-9	3.6	135
147	Effectiveness of switching antipsychotic medications. <i>American Journal of Psychiatry</i> , 2006 , 163, 2090-5	11.9	134
146	The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 500-8	4.6	125
145	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011 , 16, 76-85	15.1	124
144	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011 , 16, 321-32	15.1	123
143	A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). <i>American Journal of Psychiatry</i> , 2011 , 168, 947-56	11.9	123
142	Effectiveness of switching from antipsychotic polypharmacy to monotherapy. <i>American Journal of Psychiatry</i> , 2011 , 168, 702-8	11.9	122
141	Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005 , 80, 33-43	3.6	119
140	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 415-27	11.9	117
139	Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. <i>Journal of Nervous and Mental Disease</i> , 2006 , 194, 164-72	1.8	115
138	Causes of schizophrenia reported by patients/family members in China. <i>British Journal of Psychiatry</i> , 2000 , 177, 20-5	5.4	109
137	Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1978-87	27.4	107
136	Genomewide association study of movement-related adverse antipsychotic effects. <i>Biological Psychiatry</i> , 2010 , 67, 279-82	7.9	107
135	Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. <i>American Journal of Psychiatry</i> , 2016 , 173, 166-73	11.9	106
134	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009 , 107, 1-12	3.6	106
133	Determining when impairment constitutes incapacity for informed consent in schizophrenia research. <i>British Journal of Psychiatry</i> , 2007 , 191, 38-43	5.4	106

132	Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. <i>American Journal of Psychiatry</i> , 2013 , 170, 1032-40	11.9	94
131	Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>Schizophrenia Bulletin</i> , 2003 , 29, 33-43	1.3	91
130	Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. <i>Schizophrenia Bulletin</i> , 2013 , 39, 564-74	1.3	90
129	What CATIE found: results from the schizophrenia trial. <i>Psychiatric Services</i> , 2008 , 59, 500-6	3.3	89
128	Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. <i>Neuropsychopharmacology</i> , 2011 , 36, 616-26	8.7	87
127	Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus. <i>Hippocampus</i> , 2005 , 15, 97-103	3.5	82
126	Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Biological Psychiatry</i> , 2009 , 66, 1013-22	7.9	81
125	Geographic and clinical variation in clozapine use in the United States. <i>Psychiatric Services</i> , 2014 , 65, 186-92	3.3	75
124	The NIMH-CATIE Schizophrenia Study: what did we learn?. <i>American Journal of Psychiatry</i> , 2011 , 168, 770-5	11.9	75
123	Informing sequential clinical decision-making through reinforcement learning: an empirical study. <i>Machine Learning</i> , 2011 , 84, 109-136	4	72
122	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005 , 80, 1-8	3.6	72
121	NCAM1 and neurocognition in schizophrenia. <i>Biological Psychiatry</i> , 2007 , 61, 902-10	7.9	70
120	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005 , 187, 529-36	5.4	68
119	Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 1016-22	4.6	68
118	Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. <i>American Journal of Psychiatry</i> , 2009 , 166, 583-90	11.9	65
117	Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i>Pharmacogenomics Journal</i> , 2012 , 12, 165-72	3.5	61
116	Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. <i>Schizophrenia Bulletin</i> , 2011 , 37, 1057-65	1.3	60
115	Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 526-32	4.6	60

114	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008 , 103, 104-9	3.6	59
113	The association between weight change and symptom reduction in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2011 , 128, 166-70	3.6	57
112	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018 , 102, 1185-1194	11	55
111	Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. <i>Biological Psychiatry</i> , 2008 , 63, 32-41	7.9	54
110	Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. <i>Psychiatric Services</i> , 2006 , 57, 1110-6	3.3	52
109	Substance use and schizophrenia: adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011 , 132, 177-82	3.6	46
108	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. <i>Schizophrenia Research</i> , 2008 , 100, 39-52	3.6	45
107	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015 , 44, 1706-21	7.8	43
106	Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 669-75	4.6	43
105	Polypharmacy for schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013 , 26, 208-13	4.9	42
104	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 133-46	64.1	39
103	Assessment of Medicaid managed behavioral health care for persons with serious mental illness. <i>Psychiatric Services</i> , 2005 , 56, 1245-53	3.3	39
102	Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 295-303	4.6	39
101	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006 , 60, 933-40	2.9	36
100	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. <i>Nature</i> , 2022 ,	50.4	35
99	Schizophrenia genetic variants are not associated with intelligence. <i>Psychological Medicine</i> , 2013 , 43, 2563-70	6.9	34
98	A multiple imputation strategy for sequential multiple assignment randomized trials. <i>Statistics in Medicine</i> , 2014 , 33, 4202-14	2.3	32
97	Heterogeneity of treatment effects in schizophrenia. <i>American Journal of Medicine</i> , 2007 , 120, S26-31	2.4	32

96	The impact of obesity on health care costs among persons with schizophrenia. <i>General Hospital Psychiatry</i> , 2009 , 31, 1-7	5.6	30
95	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020 , 395, 986-997	4.0	28
94	Deaths of people with mental illness during interactions with law enforcement. <i>International Journal of Law and Psychiatry</i> , 2018 , 58, 110-116	2.6	28
93	Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 266-73	1.7	28
92	Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits. <i>Current Behavioral Neuroscience Reports</i> , 2016 , 3, 165-175	1.7	27
91	Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. <i>Schizophrenia Research</i> , 2011 , 130, 47-52	3.6	27
90	Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 75-80	4.6	26
89	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013 , 146, 190-5	3.6	24
88	Tobacco use and mental illness: a wake-up call for psychiatrists. <i>Psychiatric Services</i> , 2014 , 65, 1406-8	3.3	24
87	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1298-300	3.5	24
86	An Initiative to Improve Clozapine Prescribing in New York State. <i>Psychiatric Services</i> , 2016 , 67, 369-71	3.3	23
85	Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019 , 76, 508-515	14.5	23
84	Effectiveness of long-acting injectable antipsychotics: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2015 , 18, 36-9	11.1	22
83	A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 336-40	3.5	21
82	Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. <i>Psychiatric Services</i> , 2012 , 63, 1146-9	3.3	20
81	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 103-11	2.2	20
80	Paliperidone for schizophrenia. <i>The Cochrane Library</i> , 2008 , CD006369	5.2	19
79	Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i>Journal of Community Psychology</i> , 2011 , 39, 76-88	2.2	18

78	Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008 , 35, 215-25	1.7	17
77	Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. <i>Psychiatric Services</i> , 2016 , 67, 152	3.3	17
76	Paliperidone palmitate for schizophrenia. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1124-7	1.3	16
75	Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1587-91	2.9	16
74	Drugs of the psychopharmacological revolution in clinical psychiatry. <i>Psychiatric Services</i> , 2000 , 51, 1254-8	3.3	16
73	Management of Medical Illness in Persons With Schizophrenia. <i>Psychiatric Annals</i> , 2000 , 30, 35-40	0.5	16
72	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). <i>Frontiers in Genetics</i> , 2011 , 2, 56	4.5	15
71	Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. <i>American Journal of Veterinary Research</i> , 2006 , 67, 1173-8	1.1	15
70	Paliperidone for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2008 , 34, 419-22	1.3	13
69	Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs. <i>Psychiatric Services</i> , 2002 , 53, 293-8	3.3	13
68	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019 , 208, 182-189	3.6	12
67	Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Statistics in Biopharmaceutical Research</i> , 2011 , 3, 253-265	1.2	12
66	AKT1 and neurocognition in schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007 , 41, 169-77	2.6	12
65	Electronic health records in mental health research: a framework for developing valid research methods. <i>Psychiatric Services</i> , 2015 , 66, 193-6	3.3	11
64	Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. <i>Schizophrenia Bulletin</i> , 2008 , 34, 266-74	1.3	11
63	Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. <i>Schizophrenia Bulletin</i> , 2006 , 32, 147-52	1.3	11
62	Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	11
61	Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2021 , 78, 632-641	14.5	10

60	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016 , 67, 1124-1130	3.3	9
59	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009 , 113, 12-8	3.6	9
58	Risperidone versus olanzapine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2007 , 33, 1274-6	1.3	9
57	Criminal justice system involvement among people with schizophrenia. <i>Community Mental Health Journal</i> , 2011 , 47, 727-36	2.1	8
56	What can large simple trials do for psychiatry?. <i>American Journal of Psychiatry</i> , 2011 , 168, 117-9	11.9	8
55	No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 1115-7	3.5	7
54	Schizophrenia, VI: Treatments. <i>American Journal of Psychiatry</i> , 2003 , 160, 1748	11.9	7
53	Mortality risk of antipsychotic augmentation for adult depression. <i>PLoS ONE</i> , 2020 , 15, e0239206	3.7	7
52	Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. <i>JAMA Psychiatry</i> , 2021 , 78, 876-885	14.5	7
51	Cost-effectiveness of schizophrenia pharmacotherapy. <i>American Journal of Psychiatry</i> , 2007 , 164, 678; author reply 678-9	11.9	6
50	Correlates of family burden under medicaid managed mental health care. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2001 , 29, 117-28	3.1	6
49	Guest editors Introduction: what can large pragmatic clinical trials do for public mental health care?. <i>Schizophrenia Bulletin</i> , 2003 , 29, 1-6	1.3	5
48	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome	189-206	4
47	Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH Schizophrenia Trials Network Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007 , 1, 69-72	1.6	4
46	What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 1261-2	4.6	4
45	Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. <i>Psychiatric Services</i> , 2021 , appis202000932	3.3	4
44	An international survey examining the impact of the COVID-19 pandemic on telehealth use among mental health professionals.. <i>Journal of Psychiatric Research</i> , 2022 , 148, 188-196	5.2	3
43	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , 2019 , 4	1.7	3

42	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. <i>Journal of Clinical Psychiatry</i> , 2018 , 80,	4.6	3
41	Violence risk assessment for young adults receiving treatment for early psychosis. <i>International Journal of Law and Psychiatry</i> , 2021 , 76, 101701	2.6	3
40	Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. <i>Psychiatric Services</i> , 2018 , 69, 605-608	3.3	2
39	Drug information update: paliperidone palmitate for schizophrenia. <i>The Psychiatrist</i> , 2013 , 37, 164-166		2
38	Neurocognition97-119		2
37	Drs. Stroup, Rosenheck, Essock, and Lieberman Reply. <i>American Journal of Psychiatry</i> , 2007 , 164, 1266-1267		2
36	Dr. Lieberman and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006 , 163, 555-a-556	11.9	2
35	Revised PORT recommendations. <i>Schizophrenia Bulletin</i> , 2004 , 30, 609-11	1.3	2
34	Feasibility and Utility of Different Approaches to Violence Risk Assessment for Young Adults Receiving Treatment for Early Psychosis.. <i>Community Mental Health Journal</i> , 2022 , 1	2.1	2
33	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020 , 220, 92-97	3.6	1
32	Public-academic partnerships: a rapid small-grant program for policy-relevant research: motivating public-academic partnerships. <i>Psychiatric Services</i> , 2013 , 64, 106-8	3.3	1
31	The enduring challenge of antipsychotic non-adherence. <i>World Psychiatry</i> , 2013 , 12, 236-7	14.4	1
30	Violence in schizophrenia: prevalence, correlates, and treatment effectiveness207-236		1
29	Population pharmacokinetics of antipsychotics267-280		1
28	Extrapyramidal side effects156-172		1
27	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>Focus (American Psychiatric Publishing)</i> , 2012 , 10, 226-230	1.1	1
26	Vasodilators in aortic regurgitation. <i>New England Journal of Medicine</i> , 2006 , 354, 300-3; author reply 300-3	59.2	1
25	Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. <i>Evidence-Based Mental Health</i> , 2006 , 9, 70	11.1	1

24	Schizophrenia, drug therapy, and monitoring. <i>New England Journal of Medicine</i> , 2004 , 350, 415-6	59.2	1
23	Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. <i>Trials</i> , 2020 , 21, 871	2.8	0
22	Raising the standard of care for schizophrenia is an achievable goal. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 637-638	2.6	
21	Examination of heterogeneity in treatment response to antipsychotic medications. <i>Schizophrenia Research</i> , 2019 , 211, 100-102	3.6	
20	The need to determine the best options for people with schizophrenia that is unresponsive to treatment. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013 , 6, 1-3	0.2	
19	Response to Rosenfeld. <i>American Journal of Psychiatry</i> , 2014 , 171, 119-20	11.9	
18	Antipsychotic medications for schizophrenia--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1469	27.4	
17	Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study80-96		
16	Family outcomes133-155		
15	Study design and protocol development process1-21		
14	Statistical considerations22-38		
13	Cost-effectiveness and cost-benefit analysis57-79		
12	Metabolic side effects and risk of cardiovascular disease173-188		
11	Genetic investigations in the CATIE sample237-254		
10	Implications for research design and study implementation281-287		
9	Conclusion and implications for practice and policy288-306		
8	Human subjects considerations255-266		
7	Effectiveness and efficacy: staying on treatment and symptom reduction39-56		

6 Vocational outcomes120-132

- | | | |
|---|--|------|
| 5 | Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2010 , 13, 53 | 11.1 |
| 4 | No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differ. <i>Evidence-Based Mental Health</i> , 2011 , 14, 25 | 11.1 |
| 3 | Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Psychiatric Publishing)</i> , 2006 , 4, 539-552 | 1.1 |
| 2 | Clinical and Community-Service Activities of Psychiatric Teaching Hospitals. <i>Academic Psychiatry</i> , 1999 , 23, 123-127 | 1.1 |
| 1 | Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia525-539 | |